BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS

Foto de BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS

Foto de KU Leuven

KU Leuven

Lovaina, Bélgica

Publicacións en colaboración con investigadores/as de KU Leuven (5)

2016

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics
Nature Communications, Vol. 7

2014

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

2009

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Blood, Vol. 114, Núm. 6, pp. 1166-1173

2004

Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - A study within the Europe against cancer program [9]
Leukemia

2003

Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program
Leukemia, Vol. 17, Núm. 12, pp. 2318-2357